# Source: Myriad Genetics Form 10-K, Fiscal Year 2025 **Type:** source **Status:** Useful **Confidence:** High **Source Type:** filing **URL:** https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm **Publisher:** U.S. Securities and Exchange Commission (EDGAR) **Retrieved:** 2026-08-12 **Updated:** 2026-08-11 **Relates:** cites [Myriad Genetics](myriad-genetics.md) · https://greatutah.work/pages/myriad-genetics.md · https://www.sec.gov/Archives/edgar/data/899923/000089992326000018/mygn-20251231.htm ## Summary Myriad Genetics' annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on 2026-02-24. Accession number **0000899923-26-000018**; filer CIK **0000899923**; IRS employer identification number **87-0494517**. This is the primary record for Myriad's revenue, losses, headcount, headquarters, and laboratory footprint. Anything on the venture page that a reader would act on — how big the company is, whether it is growing, where it actually sits in Salt Lake City — should trace here rather than to the company's marketing site. The filing and its XBRL facts are retrievable indefinitely from EDGAR by CIK and accession number: `https://data.sec.gov/submissions/CIK0000899923.json` lists every filing, and `https://data.sec.gov/api/xbrl/companyconcept/CIK0000899923/us-gaap/{tag}.json` returns the tagged financial facts with their source accessions. ## Useful Claims - Total revenue for FY2025 was **$824.5 million**, down from **$837.6 million** in FY2024 (FY2023: **$753.2 million**). - Net loss for FY2025 was **$365.9 million**, against a net loss of **$127.3 million** in FY2024; basic and diluted loss per share was **$3.95**. - The FY2025 loss includes goodwill impairment charges of **$234.7 million** and intangible asset impairment charges of **$82.0 million**, related to the Women's Health and Mental Health reporting units. - Myriad had approximately **2,700 full-time equivalent employees** as of December 31, 2025. - Principal executive offices are at **322 North 2200 West, Salt Lake City, Utah 84116** — not the Research Park address carried by some third-party directories. - The Salt Lake City corporate headquarters holds approximately **234,000 square feet** of laboratory and office space; the lease runs to **2038** with renewal options. - Laboratories in Salt Lake City, Utah; Mason, Ohio; and South San Francisco, California are CLIA certified to perform high-complexity tests. - Myriad is a Delaware corporation (SIC 2835, in vitro and in vivo diagnostic substances). ## Verbatim > "During the year ended December 31, 2025, we reported total revenue of $824.5 million, a net loss > of $365.9 million, and basic and diluted loss per share of $3.95." > — Item 7, Management's Discussion and Analysis > "Goodwill and long-lived asset impairment charges for the year ended December 31, 2025 included > primarily goodwill impairment charges of $234.7 million and intangible asset impairment charges of > $82.0 million related to our Women's Health and Mental Health reporting units." > — Item 7, Management's Discussion and Analysis > "As of December 31, 2025, we had approximately 2,700 full-time equivalent employees." > — Item 1, Business (Human Capital) > "We are a Delaware corporation with our principal executive offices located at 322 North 2200 West, > Salt Lake City, Utah 84116." > — Item 1, Business (Available Information) > "Our corporate headquarters is located in West Salt Lake City, Utah, which has approximately > 234,000 square feet of laboratory and office space." > — Item 2, Properties > "The lease for our Salt Lake City facility has a remaining term of thirteen years, expiring in > 2038, and provides for renewal options for up to ten additional years." > — Item 2, Properties > "Our laboratories in Salt Lake City, Utah, Mason, Ohio, and South San Francisco, California are > CLIA certified to perform high complexity tests." > — Item 2, Properties Multi-year figures as the SEC's own XBRL API returns them, from `https://data.sec.gov/api/xbrl/companyconcept/CIK0000899923/us-gaap/RevenueFromContractWithCustomerExcludingAssessedTax.json` and `.../NetIncomeLoss.json` (`val` in USD, `accn` is the filing that reported it): ``` 2023-01-01..2023-12-31 revenue 753200000 accn 0000899923-26-000018 2024-01-01..2024-12-31 revenue 837600000 accn 0000899923-26-000018 2025-01-01..2025-12-31 revenue 824500000 accn 0000899923-26-000018 2023-01-01..2023-12-31 net income -263300000 accn 0000899923-26-000018 2024-01-01..2024-12-31 net income -127300000 accn 0000899923-26-000018 2025-01-01..2025-12-31 net income -365900000 accn 0000899923-26-000018 ``` ## Reliability Notes A Form 10-K is a primary-tier source: it is filed under securities-law accuracy duties, audited as to its financial statements, and archived permanently by the SEC. It is the highest-confidence source available for revenue, losses, headcount, and property, and it supersedes press coverage and the company's own website on all of those. Two limits worth stating. First, a 10-K is a point-in-time document — the figures above describe FY2025 and were superseded for interim periods by the Q1 and Q2 2026 Form 10-Qs (the most recent, accession 0000899923-26-000072, covers the quarter ended 2026-06-30). Second, forward-looking statements in the filing are management's expectations, not facts, and carry the filing's own safe-harbor caveats. ## Related Pages - [Myriad Genetics](myriad-genetics.md) - [Myriad Genetics BRCA Sequencing and Testing](myriad-genetics-brca.md)